by Mike Johnson (First appeared on AMRC website, 21 November 2016) Which treatment or diagnostic would make a patient’s life better? This is the starting point of what MRC Technology does. Like other medical research charities, we exist to improve patients’ lives, but unlike them, we don’t focus on a specific disease but work across a range of diseases. Many charities are doing tremendous work to support patients and fund research into potential treatments. If we work together, we can create a much bigger wave towards positive… Read More22 November 2016
Dr David Pardoe, Head of Growth Projects at MRC Technology (First appeared as part of MediaPlanet’s antibiotic resistance campaign) Antibiotic resistance As we face the prospect of living in a ‘post-antibiotic’ era, there is renewed urgency to rethink the way we approach both the research and the funding of drug innovation. When it comes to developing new drugs we typically build on the research we’ve done in the past. But in fighting gram-negative bacteria we’ve already tested everything that is likely to work, so we need a new approach.With… Read More18 November 2016
MRC Technology, UCB and the University of Leicester combine research excellence and expertise to evolve drug discovery
New research consortium aims to identify opportunities for drug discovery through the innovative use of antibodies in structure-based drug discovery and design.8 November 2016
MRC Technology and aPODD have launched a call for action to accelerate the development of new treatments for children with cancer. Around 1,500 children are diagnosed with cancer in the UK every year, and 300 will die from the disease.20 October 2016
A charity-industry collaboration has launched an initiative to find new epigenetic drug treatments to improve the lives of millions of people affected by respiratory diseases every year.1 September 2016
MRC Technology and AstraZeneca are launching an initiative to find new epigenetic drug targets in respiratory disease. They are now seeking academics with relevant epigenetics targets to collaborate with them to develop novel treatments for respiratory diseases, which affect millions of people every year.15 June 2016
MRC Technology and Keio University to collaborate on drug discovery
19 May London (UK) and Tokyo (Japan) MRC Technology and Keio University School of Medicine have signed a memorandum of understanding outlining their collaboration to identify promising antibody and small molecule research and translate them into early stage assets. By combining capabilities, the partnership aims to accelerate discovery to a stage where it is ready for clinical development by pharmaceutical companies and ultimately benefit patients.
MRC Technology, a medical research charity, aims to find treatments in areas of unmet patient needs. It offers commercialisation and intellectual property (IP) management skills and diagnostic and drug discovery expertise, specialising in small molecules and therapeutic antibodies.
Keio University is a modern institution found on ‘jitsugaku’ (science) based learning. It has developed expertise in a wide range of therapeutic areas, including cancer, cardiovascular and metabolic diseases.
MRC Technology has a similar agreement in place with Tokyo University.19 May 2016
Patent protection for biotech/genetic engineering: report
Andrew Farquarson, Director, Technology Transfer, has been a member of the EU Commission’s Expert Group appointed in 2012 to advise on the Biotech Directive and patent protection for biotech/genetic engineering inventions.
Their report has now been published.
Medical related information are on page 127 (are/should stem cells, including human embryonic stem cells, be patentable ) and page 176 (should patents on nucleic acids be use-limited).18 May 2016
MRC Technology, a medical research charity, has signed an agreement to review DEBRA Austria’s research portfolio, aiming to identify promising projects and results which could be suitable for translation into better treatments.26 April 2016
(Antibody humanised by MRC Technology) Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has awarded Keytruda (pembrolizumab) Breakthrough Therapy Designation in classical Hodgkin Lymphoma. It is the drug’s fourth breakthrough status – previously awarded for advanced melanoma, non-small cell lung cancer and colorectal cancer. Keytruda is considered a next generation drug in cancer care, stimulating the body’s immune system to fight the disease. The therapeutic is one of a new generation of PD-1 (programmed cell death protein… Read More20 April 2016